Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from QURE

Huntington's Disease Gene Therapy AMT-130 Is on Track for FDA Approval After uniQure Reaches Regulatory Agreement

uniQure announced June 17, 2026: FDA agreed that 3-year AMT-130 Phase I/II data supports an accelerated approval BLA for Huntington's disease. BLA submission planned Q3 2026.

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure stock looks poised to soar over the long term, but it does pose meaningful risk.

Breakout Momentum Plays You Need to Know About

Breakout Momentum Plays You Need to Know About

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop

Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come.

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move…

Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. The Dow Jones Industrial Average declined 0.37% to 46,121.28, while the SP 500 eased 0.3% to 6,637.97.

inkl

Read news from The Economist, FT, and more,
with one subscription

This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now?

This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now?

Uniqure shares skyrocket as the biotech firm announces a major breakthrough in Huntington’s disease. Here’s why investors should wait before initiating a new position in QURE stock.

Don't Leave Your Wellness Routine at Home — I Tried Out a Travel-Friendly Filtered Shower Head, and Here's What I Think About It

Don't Leave Your Wellness Routine at Home — I Tried Out a Travel-Friendly Filtered Shower Head, and Here's What I Think About It

Protect your skin and hair from harsh, hard water, even while vacationing, with Curo Skin's neat shower filter and vanity case kit

uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease

uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease

uniQure N.V. (NASDAQ:QURE) on Friday released initial safety and exploratory efficacy data from the first cohort of its Phase 1/2a trial of AMT-191, an investigational gene therapy for Fabry disease.

AI could solve NHS radiologist ‘workforce crisis’

AI could solve NHS radiologist ‘workforce crisis’

A study in Surrey found the technology could categorise chest X-rays with an accuracy of 99.7%

The Independent UK

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease. Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

1

Organisations

Intel Corporation

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Dow Jones Industrial Average

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

390,418 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play